KRAS and colorectal carcinoma: Arena et al. [47] observed that most CRC cell lines harboring KRAS or BRAF mutations, as well as other anti-epidermal growth factor receptor (anti-EGFR) resistance mutations, were resistant to PARP inhibitors.